Bell Biosystems, a US-based life sciences startup which graduated from Stanford University’s StartX accelerator and is backed by the Thiel Foundation’s Breakout Labs, has raised an undisclosed amount of series A funding and been accepted into the Janssen Labs life science startup incubator programme at QB3@953 in San Francisco.
The funds are being used to scale up R&D efforts, increase industry partnerships and expand collaborations with “key opinion leaders who are integrating Magnelles into their preclinical research programs.”
Magnelles are a synthetic organelle that produces magnetic nanoparticles from intracellular iron.
Caleb Bell, CEO of Bell Biosystems, said: “With this financing and compelling experimental results from our early adopters and industry partners, we are accelerating commercialization of the Magnelle. We’re thrilled that our previous investors are being joined by the Stanford-StartX Fund, top tier Silicon Valley Angels, Angel Groups and Venture Capitalists to fund our continuing efforts.”